Scienture Holdings, Inc. — 2020 Q2 Form 10-Q Summary
Entity and period: The supplied filing is for Trxade Group, Inc. (NASDAQ: MEDS), for the quarter ended June 30, 2020; it does not identify Scienture Holdings, Inc. as the registrant. Confirm the issuer identity before relying on this summary.
Business context and reporting period
Trxade operates a web-based pharmaceutical marketplace and owns pharmaceutical wholesaling, specialty pharmacy, delivery-software and telehealth businesses. Results cover the three and six months ended June 30, 2020, compared with the same periods in 2019. The statements are unaudited.
Financial results and liquidity
- Revenue: Q2 revenue was $6.59 million, up 244% year over year; six-month revenue was $8.80 million, up 156.5%. Growth was led by Integra Pharma, including N95 masks and sanitizers: six-month Integra revenue was $5.00 million versus $0.35 million.
- Profitability: Q2 gross profit was $2.00 million, with a 30.4% gross margin, compared with $1.16 million and 60.7% a year earlier. Six-month gross profit was $3.64 million and margin 41.4%, versus $2.31 million and 67.4%. Q2 operating loss was $535,277 and net loss $542,587, compared with prior-year operating income of $132,705 and net income of $57,981. Six-month net loss was $362,284 versus net income of $183,210. The company attributed the loss largely to increased stock-based compensation, including management bonus shares.
- Expenses and EPS: Q2 general and administrative expense was $2.54 million, including $1.04 million of stock-based compensation; six-month expense was $3.99 million, including $1.31 million of stock-based compensation. Basic and diluted loss per share were $0.07 for Q2 and $0.05 for six months.
- Cash flow: Operating cash used was $3.98 million for the six months, versus $79,689 in 2019, primarily reflecting increases in receivables, inventory and inventory deposits. Investing cash used was $23,505. Financing provided $5.29 million, principally from the February equity offering. Cash increased by $1.28 million to $4.15 million. A $2.575 million receivable outstanding at quarter-end was collected in July; $226,500 of inventory deposits was also returned in July.
- Liquidity and debt: Working capital was $9.40 million, versus $3.28 million at December 31, 2019; current assets were $10.12 million and current liabilities $719,825. Cash was $4.15 million. Related-party notes payable were $225,000, due October 2021; lease liabilities totaled $730,334, of which $94,253 was current. The company raised approximately $5.17 million net from its February offering after offering costs.
Material changes and outlook
- Revenue growth was substantially driven by pandemic-related sourcing of masks and sanitizers. Management said it had not yet experienced a significant adverse COVID-19 effect on revenue or gross profit, but reported pharmaceutical supply interruptions and warned these could become more frequent or material.
- Management expected Bonum Health Hub installations to be delayed until 2021 at the earliest because of COVID-19.
- Management estimated approximately $5.0 million in general and administrative and working-capital requirements for the next 12 months, and stated it believed available cash and operating cash generation would support operations for the foreseeable future. No specific revenue or earnings guidance was provided.
- Management cautioned that future capital may be needed for growth or acquisitions and may not be available on favorable terms; additional equity financing could dilute shareholders. COVID-19 risks include supply and delivery disruptions, product shortages and price volatility, weaker demand, extended customer payment terms, and possible asset impairments.
Contingencies, controls and unusual items
- A lawsuit sought $425,000 in compensatory and $1.275 million in punitive damages. The company and CEO were dismissed in May 2020 for lack of personal jurisdiction; the plaintiffs’ appeal deadline was expected in August 2020. The company could not estimate a probable or reasonably possible loss range.
- Disclosure controls and procedures were reported ineffective as of June 30, 2020, due to material weaknesses involving written accounting/reporting policies and period-end financial reporting controls. Management said it was adding personnel and technical accounting resources and developing written procedures.
- The February 2020 offering issued 922,219 shares for approximately $5.99 million gross proceeds. Outstanding shares rose to 8,062,337 at June 30, 2020 from 6,539,415 at year-end. A 1-for-6 reverse stock split took effect in February; share data was retroactively adjusted.
- The company reported no outstanding off-balance-sheet arrangements. SyncHealth, a prior equity-method investment, was divested in February 2020.
Most important facts to verify
- Confirm that Trxade Group, Inc. is the intended issuer; the request metadata names Scienture Holdings, Inc.
- Assess whether revenue and margins tied to pandemic-related mask and sanitizer sourcing are sustainable, and review subsequent-period sales and product availability.
- Verify collection of the $2.575 million receivable and return of the $226,500 inventory deposit, and monitor receivables, inventory and operating cash burn.
- Review subsequent filings for appeal activity in the dismissed lawsuit and any updated assessment of potential loss.
- Track remediation of the disclosed internal-control material weaknesses and any future financing or dilution.